ANIP vs. AUPH
ANIP (ANI Pharmaceuticals, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) are both stocks. Both are in the Healthcare sector — ANIP in Drug Manufacturers - Specialty & Generic, AUPH in Biotechnology. Over the past 10 years, ANIP returned 4.07%/yr vs 18.49%/yr for AUPH. At a 0.20 correlation, their price movements are largely independent.
Performance
ANIP vs. AUPH - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ANIP achieves a 3.47% return, which is significantly higher than AUPH's -0.82% return. Over the past 10 years, ANIP has underperformed AUPH with an annualized return of 4.07%, while AUPH has yielded a comparatively higher 18.49% annualized return.
ANIP
- 1D
- 0.04%
- 1M
- 0.99%
- YTD
- 3.47%
- 6M
- 1.60%
- 1Y
- 31.49%
- 3Y*
- 18.03%
- 5Y*
- 18.57%
- 10Y*
- 4.07%
AUPH
- 1D
- -0.19%
- 1M
- -1.31%
- YTD
- -0.82%
- 6M
- -0.19%
- 1Y
- 92.22%
- 3Y*
- 16.72%
- 5Y*
- 4.23%
- 10Y*
- 18.49%
ANIP vs. AUPH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ANIP ANI Pharmaceuticals, Inc. | 3.47% | 42.80% | 0.25% | 37.06% | -12.70% | 58.68% | -52.91% | 36.98% | -30.15% | 6.32% |
AUPH Aurinia Pharmaceuticals Inc. | -0.82% | 77.62% | -0.11% | 108.10% | -81.11% | 65.37% | -31.74% | 197.07% | 50.55% | 115.71% |
Correlation
The correlation between ANIP and AUPH is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Sep 3, 2014 | 0.20 |
Fundamentals
ANIP:
$1.76B
AUPH:
$2.18B
ANIP:
$4.26
AUPH:
$2.15
ANIP:
19.17
AUPH:
7.37
ANIP:
0.13
AUPH:
0.00
ANIP:
1.86
AUPH:
7.37
ANIP:
3.13
AUPH:
3.84
ANIP:
$923.71M
AUPH:
$298.30M
ANIP:
$486.11M
AUPH:
$267.70M
ANIP:
$234.71M
AUPH:
$153.45M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ANIP vs. AUPH — Risk / Return Rank
ANIP
AUPH
ANIP vs. AUPH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and Aurinia Pharmaceuticals Inc. (AUPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ANIP | AUPH | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.15 | ||
| Sortino ratioReturn per unit of downside risk | -0.95 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.38 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.10 | 5.83 | -4.73 |
| Martin ratioReturn relative to average drawdown | 2.06 | 12.68 | -10.62 |
Loading charts...
Drawdowns
ANIP vs. AUPH - Drawdown Comparison
The maximum ANIP drawdown since its inception was -98.81%, which is greater than AUPH's maximum drawdown of -87.58%. Use the drawdown chart below to compare losses from any high point for ANIP and AUPH.
Loading charts...
Drawdown Indicators
| ANIP | AUPH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.81% | -87.58% | -11.23% |
Max Drawdown (1Y)Largest decline over 1 year | -28.66% | -15.91% | -12.75% |
Max Drawdown (3Y)Largest decline over 3 years | -28.66% | -60.80% | +32.14% |
Max Drawdown (5Y)Largest decline over 5 years | -59.38% | -87.58% | +28.20% |
Max Drawdown (10Y)Largest decline over 10 years | -72.96% | -87.58% | +14.62% |
Current DrawdownCurrent decline from peak | -81.85% | -52.18% | -29.67% |
Average DrawdownAverage peak-to-trough decline | -79.39% | -49.21% | -30.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.33% | 7.30% | +8.03% |
Volatility
ANIP vs. AUPH - Volatility Comparison
ANI Pharmaceuticals, Inc. (ANIP) and Aurinia Pharmaceuticals Inc. (AUPH) have volatilities of 9.14% and 9.07%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ANIP | AUPH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.14% | 9.07% | +0.07% |
Volatility (6M)Calculated over the trailing 6-month period | 24.38% | 23.92% | +0.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 35.56% | 45.50% | -9.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 46.29% | 67.46% | -21.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.26% | 73.95% | -25.69% |
Dividends
ANIP vs. AUPH - Dividend Comparison
Neither ANIP nor AUPH has paid dividends to shareholders.
Financials
ANIP vs. AUPH - Financials Comparison
This section allows you to compare key financial metrics between ANI Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ANIP vs. AUPH - Profitability Comparison
ANIP - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 237.46M. Therefore, the gross margin over that period was 0.0%.
AUPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported a gross profit of 71.20M and revenue of 77.71M. Therefore, the gross margin over that period was 91.6%.
ANIP - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported an operating income of 38.89M and revenue of 237.46M, resulting in an operating margin of 16.4%.
AUPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported an operating income of 41.42M and revenue of 77.71M, resulting in an operating margin of 53.3%.
ANIP - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a net income of 29.49M and revenue of 237.46M, resulting in a net margin of 12.4%.
AUPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported a net income of 34.36M and revenue of 77.71M, resulting in a net margin of 44.2%.
Frequently Asked Questions
ANIP and AUPH have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ANIP has higher volatility (9.14%) compared to AUPH (9.07%). In terms of maximum drawdown, ANIP dropped -98.81% vs AUPH's -87.58%.
AUPH currently has the higher Sharpe Ratio (2.04 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ANIP and AUPH
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer